DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers. SMi 4 th Annual Cancer Vaccines Conference September 16, 2015
|
|
- Adelia Sparks
- 6 years ago
- Views:
Transcription
1 DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers SMi 4 th Annual Cancer Vaccines Conference September 16, 2015
2 Disclaimer Certain statements made in this presentation are forward-looking statements of NW Bio as defined by the Securities and Exchange Commission ( SEC ). All statements, other than statements of historical fact, included in this presentation that address activities, events or developments that NW Bio believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors NW Bio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of NW Bio. Investors and others are cautioned that any such statements are not guarantees of future performance. These forward-looking statements could cause actual results and developments to differ materially from those expressed or implied in such statements, including our ability to raise funds for general corporate purposes and operations, including our clinical trials, the commercial feasibility and success of our technology, our ability to recruit qualified management and technical personnel, our ability to scale up the manufacturing of our product candidates for commercialization, the success of our clinical trials and our ability to obtain and maintain required regulatory approvals for our products. Furthermore, NW Bio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this presentation should be considered in conjunction with the risk factors contained in NW Bio s recent filings with the SEC, including its most recent Form 10K. This communication is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned herein. This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part; copies circulated, or disclosed to another party, without the prior written consent of Northwest Biotherapeutics (NW Bio) are strictly prohibited. 2
3 DCVax : A Fully Personalized Immune Therapy Personalized Product: autologous (personalized) dendritic cells Allows repeat doses, ongoing treatment Personalized Targets: tumor antigens from patient s own tumor Avoids Russian Roulette Broad Scope of Targets: full set of tumor antigens Not just 1 or a few pre-selected, standardized antigens Maximize obstacles to tumor escape Excellent safety profile Some flu-like symptoms; no additional drugs, no hospital stays 3
4 Cancer Is A Personalized Disease Extensive variation among cancers Extensive variation among patients, even with same cancer Significant variations within a single patient as disease progresses Extensive heterogeneity even within a single tumor 4
5 Cancer Is A Personalized Disease LB Alexandrov et al. Nature 000, 1-7 (2013) doi: /nature
6 Two Key Issues With Existing Cancer Treatments Current treatments are largely standardized, not personalized. This raises 2 key issues Russian Roulette The patient s tumor may or may not express the targets. (e.g., EGFRvIII mutation in GBM only expressed on ~30% of GBMs) Tumor escape Tumors can and do stop expressing 1 or a few targets. But tumor cells cannot stop expressing all targets. 6
7 Personalized Treatments Vary Across A Spectrum Standardized Product Standardized Targets Personalized Profiling Personalized Product Standardized Targets Personalized Product Personalized Targets Peptide vaccines DNA vaccines Checkpoint inhibitors CAR-Ts DC vaccines with pre-selected peptide antigens DCVax 7
8 Dendritic Cells Mobilize Overall Immune System DENDRITIC CELLS the master immune cells Signals activate & biomarkers educate Dendritic Cells INNATE IMMUNE SYSTEM First-responders (within hours/days) Response is automatic Response is non-specific (not tailored to each particular threat) Natural Killer Cells, Neutrophils, Granulocytes, Macrophages ADAPTIVE IMMUNE SYSTEM Follow-on defense (within week or weeks) Response is triggered by exposure to particular threat (activation + education ) Response is specific & creates memory (tailored to each particular threat) HUMORAL IMMUNITY B Cells Antibodies CELLULAR IMMUNITY Helper T Cells Killer T Cells Tumor Cell Death 8
9 Large Multiplier: Each Dendritic Cell Activates Hundreds of Anti-Cancer T Cells Dendritic Cell activated anti-cancer T cells travel to tumor site tumor target proteins anti-cancer T cell activated resting anti-cancer T cell attaches to DC activated anti-cancer T cells divide rapidly 9
10 DCVax Potentially Applicable to All Types of Solid Tumors (Both Operable & Inoperable) Market Product Composition Lead Program All Operable Solid Tumors DCVax -L Dendritic cells + biomarkers from tumor tissue sample surgically removed Brain cancer 348-patient Phase III trial underway Small ovarian cancer Phase I/II trial completed All Inoperable Solid Tumors DCVax - Direct Dendritic cells injected directly into tumor(s) + biomarkers picked up onsite in tumor All solid tumor cancers 60-patient Phase I/II trial underway Other Hormone independent prostate cancer DCVax - Prostate* Dendritic cells + recombinant prostate cancer biomarker (PSMA) Prostate cancer 600-patient Phase III trial previously cleared by FDA * The Company will seek to out-license this program 10
11 DCVax Is Expanding the Reach of Immunotherapy Front line treatment for newly diagnosed disease DCVax-L for newly diagnosed GBM, with SOC (Phase III) Front line treatment for lower grade cancers DCVax-L for all grades of gliomas, with SOC (Hosp. Exemp., Germany) Treatment for patients with very heavy tumor burdens DCVax-L for late stage, metastatic ovarian cancer DCVax-L for rapid progressor GBM DCVax-Direct for 4-5+ inoperable metastatic tumors DCVax-Direct for very large tumors (10 cm. lung; 15x19x17 cm. sarcoma) Long tail of Overall Survival 11
12 Potentially Complementary With Checkpoint Inhibitors Large number of checkpoints built into the immune system Response rates (%s) to single checkpoint inhibitors limited to date T cells must be activated, to express checkpoints DCVax activates T cells DCVax mobilizes diverse T cell populations against diverse tumor antigens (targets) Source: Allison, J. (2014). Targeting Immune Checkpoints in Cancer Therapy: New Insights and Opportunities, meetings/sitc2014/primer 12
13 Potentially Complementary With T Cell & Targeted Therapies T cell therapies (CAR-Ts, TCR, etc.) Focus on a particular tumor antigen (CD-19, EGFR, etc.) Designed to boost T cell numbers, affinity, etc. for that antigen Durability not yet clear Addressing diverse antigens may be more important in solid tumors Targeted therapies Focus on a particular cellular pathway Alternate/redundant pathways, tumor escape are an issue DCVax offers broad spectrum anti-tumor action which can complement key rifle shots 13
14 Robust Pipeline of DCVax Programs DCVax -L: Brain cancer Phase III under way (348 pts) Brain cancer Info Arm outside trial (51 pts) Brain cancer Hospital Ex./Other Early Access Metastatic ovarian cancer Phase I completed Compassionate use diverse cancers DCVax - Direct: All solid tumor cancers Phase I/II underway Additional Phase II trial(s) -- pending Pre-clinical Ph I Ph II Ph III DCVax - Prostate Hormone indep. -- Phase I/II completed (36 pts) 14
15 DCVax Direct Program
16 DCVax-Direct: Underlying Biology Immature DCs will effectively take up antigens (biomarkers) in situ in tumors, but will not activate T cells. Also, immature DCs are highly susceptible to suppression by the tumor. Mature DCs will not effectively take up antigens in situ in tumors, but will present antigens to T cells and activate them. ****************************** Partially mature, activated DCs. at a certain stage. will effectively take up antigens (biomarkers) in situ in tumors, and will effectively present antigens to T cells and activate them. 16
17 DCVax-Direct: Activated DCs CD1a: DC-specific marker involved in antigen presentation (not on all DCs, and large patient-to-patient variability) CD209: DC-specific marker involved in binding pathogens (also found on macrophages) pstat-1: phosphorylated STAT-1 signal transduction pathway molecule required for IL-12 production MHC-I, II: MHC molecules involved in antigen presentation CD83: DC activation marker CD40, CD80, CD86: surface molecules involved in T cell activation
18 DCVax Direct: Potential Clinical Effects Possible Clinical Effects Causes Seen in Pre Clinical Studies? Local effects in tumors injected with DCVax-Direct Tumor necrosis (tumor cell death) Secretion of cytokines (e.g., TNFα, IL-6, IL-8) by activated DCs Systemic effects in tumors not injected Tumor shrinkage or elimination Immune system activation Immune memory Lack of recurrence even when re-challenged Immune system activation 18
19 DCVax-Direct Phase I Trial: Overview 40 patients enrolled; 39 evaluable Patients had multiple metastases; had failed other treatments 13 different cancers treated 3 dose levels tested: 2M, 6M and 15M cells Only 1 tumor injected; treatments widely spaced Feasibility of image-guided injections tested (multiple methods) Both imaging and biopsies used to monitor responses, correlate with clinical outcomes and evaluate treatment schedule Both local and systemic responses evaluated Safety and potential endpoints evaluated 19
20 DCVax-Direct Phase I Trial -- Highlights Half of patients still alive, at up to ~22 mos. after first injection Treatment effects observed in diverse cancers Survival correlates with dose levels Survival correlates with number of injections Survival correlates with absence of progression Stable disease (SD) at Wk 8 (4 th injection visit) strongly correlates with survival 21 of 35 patients achieved SD at Wk 8 (progression data n/a on 4 pts) Encouraging immunological responses observed post treatment Induction of immune checkpoint expression Both local effects (in injected tumor) and systemic effects (in non-injected tumors) observed 20
21 DCVax-Direct Phase I Trial Update: Ongoing OS As of Sept 2015 Pancr mcrc Sarcoma mcrc Pancr NET Melan Other Lung Melan Breast mcrc Lung Lung NET Ovarian Bladder NET Pancreas Sarcoma Sarcoma Sarcoma Sarcoma Sarcoma Sarcoma mcrc Melan Melan Sarcoma Pancr Desmo Melan mcrc Pancr NET Melan Lung mcrc Pancreas mcrc Pancr Breast Alive Dead Months
22 Dose Level Correlates With Survival As of Feb Alive Dead million 6 million 15 million 22
23 Number of Injections Correlates With Survival As of Feb Alive Dead injections 3 injections 4 injections 5 injections 6 injections 23
24 Tumor Control (Stable Disease At Week 8) Correlates With Survival As of Feb 2015 p= alive dead SD week 8 PD week 8 24
25 Stable Disease at Week 8 Correlates With Survival As of Sept p=0.031 Proportion Alive Months
26 TNFα Correlates With SD vs. PD At Week 8 As of Feb 2015 p<0.01 In a multivariate analysis, TNFα production is significantly associated with survival (p=0.018) 26
27 IL-8 Production Correlates with Survival As of Feb IL-8 >1,000 Proportion alive IL-8 <1, Months
28 Immunological Responses: Tumor Infiltrating T Cells TILs, including both CD4 + helper T cells and CD8 + killer T cells increased from baseline in 15 of 27 assessed patients Example: clear cell sarcoma CD3 CD4 CD8 Day 0 Day 7 TILs sharing sequences with peripheral T cells also increased, indicating a systemic response 28
29 Immunological Responses: Intra-tumoral Responses Day 0 CD3 + T cells Interferon gamma TNF α Week 8 Expression of T cell cytokines demonstrate anti-tumor activity of infiltrating T cells following DCVax-Direct administration 29
30 Induction of Immune Checkpoint Expression Expression of immune checkpoint molecules in tumor tissue modulates antitumor immune responses Checkpoint inhibitors (CIs) can unblock an existing anti-tumor immune response, but may be ineffective in absence of such pre-existing response 14 of 22 evaluable patients (64%) in DCVax-Direct Phase I trial, showed either de novo or significantly increased expression of the PDL-1 checkpoint molecule after DCVax-Direct treatment; potential candidates for CI treatment Example: De novo PDL-1 staining on sarcoma tissue, 8 weeks after initiation of DCVax-Direct treatment 30
31 PD-L1 On Macrophages In Tumor Correlates With Survival As of Sept Emerging or significantly increased PD-L1 expression 0.8 Proportion Alive No emerging or significantly increased PDL-1 expression Months
32 Phase II Trial Plans Injection of multiple tumors, as well as multiple injections into larger tumors, at each visit More frequent injection schedule Indications with promising activity, as well as diverse indications Soft tissue sarcoma Include Quality of Life measurements Trials both in US and outside US 32
33 DCVax L Program
34 DCVax-L for Operable Tumors: Newly Diagnosed GBM PHASE I/II TRIALS 20 newly diagnosed GBM; 14 recurrent GBM; 5 lower grade gliomas Standard of care (surgery & 6 weeks radiation & chemo) + DCVax-L Primary endpoint: safety; Secondary endpoint: progression free survival Standard of Care* Matched Concurrent DCVax-L Controls** Progression 6.9 mos 8.1 mos 2 years (Tumor Recurrence) Overall Survival 14.6 mos 17 mos 3 years Long Tail of Survival 2 3% alive at 5 years To date: 33% alive >4 yrs 27% alive >6 yrs 2 pts alive >12 yrs * N Engl J Med 352: , 2005 **matched for age, gender, Karnofsky score, extent of surgical resection, and same std of care treatment, at same hospital, in same time period 34
35 International Phase III Trial With DCVax-L for GBM Newly diagnosed GBM; trial under way in both US & Europe 348 patient, randomized (2:1), double blind, placebo controlled Phase III trial: the gold standard in clinical trial design o o Primary endpoint: PFS (progression free survival) Secondary endpoints include OS (overall survival) o 3 DCVax-L treatments upfront (Day 0, 10, 20), then 3 boosters (months 2, 4, 8) then 4 treatments twice/year for maintenance phase (months 12, 18, 24, 30) Multiple protections built into trial design 4-month extension of PFS required to meet primary endpoint (less than 1/3 as long as extension of PFS seen in Phase I/II trials) Trial designed to reach p value = 0.02 if 4-month difference in PFS shown Trial also powered for secondary endpoint of Overall Survival Multiple sub-group analyses were prospectively included 35
36 Information Arm open label, for patients with apparent PD post chemo-radiation 51 patients had evidence (25% increase or new lesion) of apparent disease progression in imaging at Baseline Visit following 6 weeks chemo radiation Patients re imaged at Month 2 after Baseline Visit to confirm actual disease progression (another 25% increase or new lesion) (patients categorized by independent medical imaging company) 20 patients had further progression (another 25% increase or new lesion) at Month 2: Rapid Progressors 25 patients had stable disease, or modest (<25%) progression or some (<25%) regression at Month 2 Indeterminate 1 patient had all original 25% increase gone at Month 2: Confirmed Pseudoprogressor 5 patients Unclassified due to lack of images 36
37 20 Rapid-Progressor Patients: OS in Sept. vs Jan Patient alive in Jan remains alive; OS now > 3-1/2 years Overall, median OS 15.3 months (with Std of Care, months) Alive Dead Recurrent GBM median OS months in literature Months
38 25 Indeterminate Patients: OS in Sept. vs Jan Only 1 patient died during Jan. to Sept, % of patients (10 of 25) now have OS approx. 3 years 20% of patients now have OS 3-1/2 years Median OS is 21.5 months (vs months with Std of Care) Alive Sept 2015 ** Alive Jan ** ** (extension periods vary based on timing of data collection) Dead Sept 2015 Dead Jan Months Median OS of regular GBM patients with Std of Care: ~14.6 mos
39 DCVax -L: Cost-Effective, Rapid Batch Manufacturing DAY 1: Tumor tissue & blood at manufacturing facility. DAY 2: Precursors of dendritic cells isolated. DAY 2-7: Precursors differentiated into dendritic cells. DAY 7: DAY 8: Dendritic cells educated by exposure to biomarkers from tumor tissue. Educated dendritic cells harvested & frozen. Manufacturing finished. (Release tests follow) Single manufacturing run yields 3 5 years of doses of DCVax L product. Only 2 grams of tumor tissue needed for full batch. With <2 grams of tumor tissue, a partial batch can be produced. 39
40 Manufacturing Established At Logistics Hubs In US & Europe Memphis, TN: worldwide hub for both FedEx & UPS 80,000 sq ft facility; capacity for up to 5,000 DCVax patients/year Leipzig, Germany: Europe-wide hub for DHL, Lufthansa Cargo, others 40
DCVax Novel Personalized Immunotherapies for Solid Tumors
DCVax Novel Personalized Immunotherapies for Solid Tumors Phaciliate Immunotherapy World Forum January 26, 2016 Disclaimer Certain statements made in this presentation are forward-looking statements of
More informationCorporate Overview. Jefferies 2014 Global Healthcare Conference. June 4, 2014
Corporate Overview Jefferies 2014 Global Healthcare Conference June 4, 2014 Disclaimer Certain statements made in this presentation are forward-looking statements of NW Bio as defined by the Securities
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationORYX Translational Medicine. Dr. Bernard Huber/ CEO
ORYX Translational Medicine Dr. Bernard Huber/ CEO ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationCANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY
CANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY Peter Skorpil VP Business Development peter.skorpil@targovax.com Cutting Edge Oslo 2016-10-18 www.targovax.com 1 Important notice and disclaimer This report
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationORYX Translational Medicine. Dr. Dr. Sven Rohmann/ CBDO
ORYX Translational Medicine Dr. Dr. Sven Rohmann/ CBDO ORYX Overview Ø ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany
More informationORYX Translational Medicine. Dr. Bernard Huber / CEO
ORYX Translational Medicine Dr. Bernard Huber / CEO BIO International Convention June 2016 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationCEL-SCI Corporation. NYSE American: CVM
CEL-SCI Corporation NYSE American: CVM Geert Kersten Chief Executive Officer 8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460 Forward Looking Statements This presentation includes
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for Glioblastoma: CMV-LAMP-Vax Executive Summary Executive Summary pp65-lamp-vax First Line Therapy for Glioblastoma Multiforme
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationCopyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview
Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationImmunotherapy of Prostate Cancer
Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines
More informationDendritic Cell Based Cancer Vaccine Development
Dendritic Cell Based Cancer Vaccine Development November 10, 2005 CVCWG Meeting Rob Hershberg, MD, PhD Chief Medical Officer 1 Meeting the challenges of developing cancer vaccines-- APC8015 (Provenge TM
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationDCVax Update on Clinical Programs
DCVax Update on Clinical Programs Industry Expert Theater at ASCO Conference June 5, 2017 Marnix L. Bosch, MBA, PhD Chief Technical Officer Northwest Biotherapeutics Disclaimer Certain statements made
More informationThe Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018
The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationTumor Antigens in the Age of Engineered T cell Therapies
Tumor Antigens in the Age of Engineered T cell Therapies September 30 th 2016 ESMO Preceptorship Course Amsterdam Carsten Linnemann, PhD Senior Scientist Kite Pharma EU B.V. Amsterdam Forward Looking Statements/Safe
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationMOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO
Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationINTERIM RESULTS AS OF JUNE 30, 2017
INTERIM RESULTS AS OF JUNE 30, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationAsterias Biotherapeutics NYSE American: AST
Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE American: AST November 2017 Forward-Looking Statements Statements
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationNewLink Genetics Corporation
Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationCelldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO
November 24, 2013 Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO Strong interim survival trend (12.0 vs 7.9
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationProstate Cancer Panel. June 2018
Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash
More informationDCVax Update on Clinical Programs
DCVax Update on Clinical Programs Cancer Vaccines and Neoantigens August 31, 2017 Marnix L. Bosch, MBA, PhD Chief Technical Officer Northwest Biotherapeutics Disclaimer Certain statements made in this
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationLAG-3: Validation Of Next Generation Checkpoint Pathways
LAG-3: Validation Of Next Generation Checkpoint Pathways Frédéric Triebel, CO/CMO Immune Checkpoint Modulation & Combination Therapies April 13, 2016 London, UK. 1 AX:PRR; NADAQ:PBMD Notice: Forward Looking
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationLiving Immunotherapies. Corporate Presentation OCTOBER 2018
Living Immunotherapies Corporate Presentation OCTOBER 2018 All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation
More informationUtrophin Modulation: A Universal Treatment Approach to DMD. End Duchenne Tour April 2018
Utrophin Modulation: A Universal Treatment Approach to DMD April 2018 Legal Disclaimer Statements in this presentation, other than statements of historical fact, constitute forward-looking statements within
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationNew Generation of T-cell Therapeutics
New Generation of T-cell Therapeutics Corporate Overview January 2017 NASDAQ: TPIV 1 Safe Harbor Statement Certain statements contained herein are forward-looking statements within the meaning of the safe
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More information2010 ASCO Annual Meeting Chicago, IL June 4 - June 8, 2010
2010 ASCO Annual Meeting Chicago, IL June 4 - June 8, 2010 Abstract ID: 2546 Poster Board #: 1H A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol
More informationFrédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationMOLOGEN AG Jefferies 2014 London Healthcare Conference
Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring
More informationINTERIM RESULTS AS OF JUNE 30, 2016 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2016 Q2 CSE/OMX:BAVA, OTC:BVNRY FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationSTUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017
STUDY 1 PHASE 3 TOP-LINE RESULTS September 2017 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationA Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions
A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More information